ArticleCancer gene therapy2001
Adenovirus-mediated expression of HSV1-TK or Fas ligand induces cell death in primary human glioma-derived cell cultures that are resistant to the chemotherapeutic agent CCNU.
Article in Cancer gene therapy, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 38 citations in OpenAlex.
- Molecular Imaging with Reporter Genes: Has Its Promise Been Delivered?Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Review
- Review
- Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System.Clinical Medicine Insights. Oncology · 2011Article
- Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety.Current gene therapy · 2009Review
- Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity.Clinical cancer research : an official journal of the American Association for Cancer Research · 2009Article
- Gene therapy as an adjuvant treatment for malignant gliomas: from bench to bedside.Journal of neuro-oncology · 2009Review
- Pharmacotherapy for adults with tumors of the central nervous system.Pharmacology & therapeutics · 2009Review
- Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model.Neuro-oncology · 2008Article
- Regulated expression of adenoviral vectors-based gene therapies: therapeutic expression of toxins and immune-modulators.Methods in molecular biology (Clifton, N.J.) · 2008Article
- Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression.Journal of neuro-oncology · 2007Article
- Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro.Neuro-oncology · 2007Article
- 4-IBP, a sigma1 receptor agonist, decreases the migration of human cancer cells, including glioblastoma cells, in vitro and sensitizes them in vitro and in vivo to cytotoxic insults of proapoptotic and proautophagic drugs.Neoplasia (New York, N.Y.) · 2007Article
- Adenoviral-mediated gene transfer into the canine brain in vivo.Neurosurgery · 2007Article
- Immunological thresholds in neurological gene therapy: highly efficient elimination of transduced cells might be related to the specific formation of immunological synapses between T cells and virus-infected brain cells.Neuron glia biology · 2006Article
- Effective high-capacity gutless adenoviral vectors mediate transgene expression in human glioma cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2006Article
- FAS associated phosphatase (FAP-1) blocks apoptosis of astrocytomas through dephosphorylation of FAS.Journal of neuro-oncology · 2005Article
- Variability in infectivity of primary cell cultures of human brain tumors with HSV-1 amplicon vectors.Gene therapy · 2005Article
- Combining cytotoxic and immune-mediated gene therapy to treat brain tumors.Current topics in medicinal chemistry · 2005Review
- Apoptosis in gliomas: molecular mechanisms and therapeutic implications.Journal of neuro-oncology · 2004Review
- Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders.International review of neurobiology · 2003Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to minimal treatment success with surgery, radiotherapy, and chemotherapy, the aim of this study was to test the therapeutic potential of gene therapy for the treatment of glioblastoma multiforme (GBM). We have quantitatively analyzed two gene therapy approaches using short-term human glioma cell cultures derived from surgical biopsies (designated IN859, IN1612, IN2045, IN1760, and IN1265) and compared the results of gene therapy with the chemosensitivity of the same cells. All of the glioma cell cultures tested were susceptible to recombinant adenovirus (RAd)-mediated infection. Expression of herpes simplex virus type 1-thymidine kinase (RAd128), followed by ganciclovir treatment, induced apoptosis in all of the glioma cell cultures studied, including three that are resistant to the chemotherapeutic drug 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU). Expression of murine Fas ligand (RAdhCMV-mFasL) also induced cell death in four of the five cell cultures studied. One cell culture that was resistant to CCNU was also resistant to apoptosis induced by mFasL expression. These results suggest that sensitivity to chemotherapeutic agents does not necessarily correlate with the sensitivity to gene therapy treatments. RAds expressing therapeutic gene products in human glioma cell cultures are able to induce apoptosis even in some cells that are resistant to a commonly used chemotherapeutic agent. Therefore, RAd-mediated gene transfer could be a good candidate to further develop gene therapy for the treatment of GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.